How CHF Solutions is using health economics to expand product adoption

Two years after CHF Solutions (NSDQ:CHFS) acquired Baxter‘s (NYSE:BAX) Aquadex fluid filtration device for $5 million, the company’s executives are working to weave together the evidence they need to land reimbursement in the U.S. and expand patient access for its technology.

The Aquadex system is designed to filter water and salt from patients experiencing fluid overload due to heart failure. CHF Solutions, formerly known as Sunshine Heart, has plenty of clinical evidence to back up the device’s efficacy, according to VP of quality assurance & regulatory affairs Megan Brandt.

See Brandt address the latest trends in medtech policy at DeviceTalks Minnesota June 4-5

“Now I’m working to pull that economic story together, based off of clinical data that we have. While we may not have reimbursement, we can show that if you treat with our product, you can reduce hospital readmissions,” Brandt told MassDevice.com ahead of her appearance this summer at DeviceTalks Minnesota.

Get the full story at our sister site, MassDevice.com

Only a Few More Days to Register for the most anticipated conference of the winter! DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry. Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry. REGISTER NOW Use code LASTCHANCE to save an additional 20%.